AU2022273787B2 - Solid forms of a modulator of hemoglobin - Google Patents

Solid forms of a modulator of hemoglobin Download PDF

Info

Publication number
AU2022273787B2
AU2022273787B2 AU2022273787A AU2022273787A AU2022273787B2 AU 2022273787 B2 AU2022273787 B2 AU 2022273787B2 AU 2022273787 A AU2022273787 A AU 2022273787A AU 2022273787 A AU2022273787 A AU 2022273787A AU 2022273787 B2 AU2022273787 B2 AU 2022273787B2
Authority
AU
Australia
Prior art keywords
compound
hemoglobin
pharmaceutical composition
crystalline compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022273787A
Other languages
English (en)
Other versions
AU2022273787A1 (en
Inventor
Travis Lee Houston
Courtney S. Johnson
Stephan D. Parent
Fang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of AU2022273787A1 publication Critical patent/AU2022273787A1/en
Application granted granted Critical
Publication of AU2022273787B2 publication Critical patent/AU2022273787B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU2022273787A 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin Active AU2022273787B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
US63/188,833 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Publications (2)

Publication Number Publication Date
AU2022273787A1 AU2022273787A1 (en) 2023-10-26
AU2022273787B2 true AU2022273787B2 (en) 2025-04-03

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273787A Active AU2022273787B2 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Country Status (13)

Country Link
US (2) US11851424B2 (https=)
EP (1) EP4337659A1 (https=)
JP (1) JP2024520897A (https=)
KR (1) KR20240008356A (https=)
CN (1) CN117337285A (https=)
AR (1) AR126649A1 (https=)
AU (1) AU2022273787B2 (https=)
BR (1) BR112023021606A2 (https=)
CA (1) CA3219786A1 (https=)
MX (1) MX2023012156A (https=)
TW (1) TW202311254A (https=)
WO (1) WO2022241278A1 (https=)
ZA (1) ZA202309517B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250041312A1 (en) * 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
TW202515579A (zh) * 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
SG10201802911RA (en) * 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2022241286A1 (en) * 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Methods of making a modulator of hemoglobin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Also Published As

Publication number Publication date
MX2023012156A (es) 2023-10-26
BR112023021606A2 (pt) 2023-12-19
CN117337285A (zh) 2024-01-02
ZA202309517B (en) 2024-06-26
EP4337659A1 (en) 2024-03-20
US20220363674A1 (en) 2022-11-17
US11851424B2 (en) 2023-12-26
AR126649A1 (es) 2023-11-01
US12473277B2 (en) 2025-11-18
JP2024520897A (ja) 2024-05-27
AU2022273787A1 (en) 2023-10-26
TW202311254A (zh) 2023-03-16
US20240076290A1 (en) 2024-03-07
CA3219786A1 (en) 2022-11-17
KR20240008356A (ko) 2024-01-18
WO2022241278A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US12473277B2 (en) Solid forms of a modulator of hemoglobin
KR20160118204A (ko) 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
US20250206765A1 (en) Crystals
KR102718111B1 (ko) 노보비오신 유사체 및 프롤린의 공-결정 형태
US20250145622A1 (en) Solid forms of a triazine derivative as cbl-b modulator
EP3853200B1 (en) Erbumine salt of treprostinil
HK40101540A (zh) 血红蛋白之调节剂的固体形式
US20250304635A1 (en) Birinapant polymorph h
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
WO2021001457A1 (en) Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
CZ2015834A3 (cs) Pevná forma dapagliflozinu
KR20250107260A (ko) 2-(4-(2-(7,8-디메틸-[1,2,4]트리아졸로[1,5-a] 피리딘-6-일)-3-이소프로필-1H-인돌-5-일)피페리딘-1-일)아세트아미드 염 및 그의 결정질 형태
WO2026024591A1 (en) Tryptamine prodrug solid forms
EA043230B1 (ru) Эрбуминовая соль трепростинила
HK1187046B (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
HK1187046A (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
NZ620948B2 (en) Noribogaine salt ansolvates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)